Compare Gilead Sciences, Inc. (GILD) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Unilever plc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Unilever plc trades at $62.2 (market cap $132.07B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Unilever plc pays the higher dividend (3.48%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Unilever plc for 112 Days on average.
| GILD | UL | |
|---|---|---|
Market Cap | $182.09B | $132.07B |
Volume | 4,960,247 | 2,873,862 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $74.59 |
52-Week Low | $116.74 | $55.05 |
Typical Hold Time | 111 Days | 112 Days |
Enterprise Value | $205.15B | $157.21B |
Dividend Yield | 2.23% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Unilever (UL) trades at $61.94, up 1.88% today, amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 18.32% net margins and 54.56% ROE, though recent quarters saw EPS misses. Cash flow turned negative in 2025 at -$2.08B due to increased investing activity. The company is restructuring its portfolio, including the planned $65B food business merger with McCormick, while facing regulatory scrutiny in the UK.
Outlook remains cautious with analyst consensus divided (24% Buy, 51% Hold) and technical indicators bearish. Investment appeal lies in emerging market exposure and dividend stability, but risks include integration challenges from the McCormick deal, competitive pressures, and inconsistent earnings delivery. Valuation at 21.32 P/E appears reasonable given margins but requires execution improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
